More Approvals, Broader Indications Could Make TPD A Mainstream Modality

Johannes Yeh says targeted protein degradation will feel mainstream when the field sees more FDA approvals, stronger clinical follow-up, and expansion beyond oncology into areas such as cardiovascular disease, Alzheimer’s, autoimmune disease, and diabetes. Maria Soloveychik adds that clinical proof of tissue-selective E3 ligase biology would be a major milestone, showing the modality can deliver the selectivity drug developers are seeking.